GlassScriptPhysician profile
Joseph A Bata
NPI 1750972113
$4,867.34
in general payments reported to CMS, 2019-2025
41 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $129 · 2022: $909 · 2023: $1,276 · 2024: $1,369 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,829.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $558.09 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $442.33 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $297.26 | 2021-2025 | Evenity, Prolia, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.61 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $262.63 | 2022-2025 | |
| Corcept Therapeutics | $230.09 | 2022-2025 | Korlym |
| Antares Pharma, INC. | $229.88 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Sanofi-Aventis U.S. LLC | $228.80 | 2022-2024 | |
| Abbvie INC. | $183.17 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $168.97 | 2021-2025 | Unithroid |
| Halozyme INC | $165.01 | 2023 | |
| Alvogen INC | $150.36 | 2022-2025 | Teriparatide |
| Radius Health, INC. | $121.95 | 2022-2025 | Tymlos |
| Xeris Pharmaceuticals, INC. | $121.71 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $96.14 | 2022-2025 | Dexcom G6 Transmitter |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $92.21 | 2021-2023 | Somatuline Depot |
| Beta Bionics, INC. | $90.92 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Evoke Pharma, INC. | $87.65 | 2021-2024 | Gimoti |
| Neurocrine Biosciences, INC. | $83.89 | 2024-2025 | |
| Mannkind Corporation | $72.02 | 2022-2025 | Afrezza |
| Amryt Pharma Holdings LTD | $70.61 | 2022-2023 | Mycapssa |
| Verity Pharmaceuticals INC. | $68.76 | 2024-2025 | Tlando |
| Pfizer INC. | $66.63 | 2022-2025 | |
| Ascendis Pharma Endocrinology INC | $62.26 | 2025 | Yorvipath |
| Recordati_rare_diseases_inc. | $59.96 | 2024-2025 | Isturisa, Signifor Lar |
| Esperion Therapeutics, INC. | $56.31 | 2023-2024 | Nexletol |
| Medtronic, INC. | $53.07 | 2024-2025 | Minimed 780g |
| Ascensia Diabetes Care US INC. | $46.67 | 2024-2025 | |
| Amphastar Pharmaceuticals, INC. | $44.37 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $44.16 | 2022 | |
| Currax Pharmaceuticals LLC | $41.25 | 2021-2023 | Contrave |
| Insulet Corporation | $38.30 | 2024 | Omnipod |
| Cequr Corporation | $37.13 | 2022-2024 | Cequr Simplicity |
| Lifescan, INC. | $37.06 | 2022 | |
| Acella Pharmaceuticals, LLC | $33.32 | 2024-2025 | NP Thyroid 60 |
| Tolmar, INC. | $32.70 | 2023-2025 | Jatenzo |
| Averitas Pharma INC. | $31.15 | 2023 | Qutenza |
| Rhythm Pharmaceuticals, INC. | $20.25 | 2025 | Imcivree |
| Azurity Pharmaceuticals, INC. | $16.96 | 2025 | Azmiro |
| Kyowa Kirin, INC. | $16.15 | 2025 | |
| Amarin Pharma, INC. | $15.58 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Bata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.